EP0833641A4 - Behandlung und vorbeugung von erkrankungen der prostata - Google Patents

Behandlung und vorbeugung von erkrankungen der prostata

Info

Publication number
EP0833641A4
EP0833641A4 EP96917173A EP96917173A EP0833641A4 EP 0833641 A4 EP0833641 A4 EP 0833641A4 EP 96917173 A EP96917173 A EP 96917173A EP 96917173 A EP96917173 A EP 96917173A EP 0833641 A4 EP0833641 A4 EP 0833641A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
prostatic diseases
prostatic
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96917173A
Other languages
English (en)
French (fr)
Other versions
EP0833641A1 (de
Inventor
Roy G Smith
William Rosner
Atif M Nakhla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Lukes Roosevelt Hospital Center
Merck and Co Inc
Original Assignee
St Lukes Roosevelt Hospital Center
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Lukes Roosevelt Hospital Center, Merck and Co Inc filed Critical St Lukes Roosevelt Hospital Center
Publication of EP0833641A1 publication Critical patent/EP0833641A1/de
Publication of EP0833641A4 publication Critical patent/EP0833641A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP96917173A 1995-06-07 1996-06-05 Behandlung und vorbeugung von erkrankungen der prostata Withdrawn EP0833641A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48463395A 1995-06-07 1995-06-07
US484633 1995-06-07
PCT/US1996/008873 WO1996040150A1 (en) 1995-06-07 1996-06-05 Treatment and prevention of prostatic disease

Publications (2)

Publication Number Publication Date
EP0833641A1 EP0833641A1 (de) 1998-04-08
EP0833641A4 true EP0833641A4 (de) 2000-04-05

Family

ID=23924956

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917173A Withdrawn EP0833641A4 (de) 1995-06-07 1996-06-05 Behandlung und vorbeugung von erkrankungen der prostata

Country Status (5)

Country Link
EP (1) EP0833641A4 (de)
JP (1) JPH11507050A (de)
AU (1) AU5984196A (de)
CA (1) CA2222625A1 (de)
WO (1) WO1996040150A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488807A4 (de) * 2002-03-11 2009-07-08 Takeda Pharmaceutical Mittel zur behandlung von sexualhormonabhängigen erkrankungen
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
WO2004071533A1 (ja) * 2003-02-14 2004-08-26 Takeda Pharmaceutical Company Limited 局所投与用製剤
WO2006081658A1 (en) * 2005-02-01 2006-08-10 The University Of British Columbia In silico screening for shbg binding ligands via pharmacophore models
US8361996B2 (en) * 2005-09-15 2013-01-29 Council Of Scientific And Industrial Research Imidazolyl substituted steroidal and indan-1-one derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000095A1 (en) * 1989-06-27 1991-01-10 Michael Cohen Compositions useful as contraceptives in males
WO1994018936A1 (en) * 1993-02-19 1994-09-01 Ringler, Steven, L. Compositions and methods for promoting hair growth
WO1995004535A1 (en) * 1993-08-06 1995-02-16 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000095A1 (en) * 1989-06-27 1991-01-10 Michael Cohen Compositions useful as contraceptives in males
WO1994018936A1 (en) * 1993-02-19 1994-09-01 Ringler, Steven, L. Compositions and methods for promoting hair growth
WO1995004535A1 (en) * 1993-08-06 1995-02-16 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NAKHLA, A. M. ET AL.: "Sex hormone-binding globulin (SHBG) and estradiol, but not dihydrotestosterone, act together to increase intracellular cAMP in human benign prostatic hypertrophy.", JOURNAL OF UROLOGY, vol. 151, no. 5, 1994, pages 382A, XP002128737 *
PLYMATE S.R. ET AL.: "Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma", J. STEROID BIOCHEM MOL BIOL, vol. 40, no. 4-6, 1991, USA, pages 833 - 9, XP002128736 *
SCHMIDT, K.: "Effect of radix urticae extract and its several secondary extracts on blood SHBG in benign prostate.", FORTSCHRITTE DER MEDIZIN, vol. 101, no. 15, 1983, pages 713 - 6, XP002128738 *
See also references of WO9640150A1 *
VERHELST, J. ET AL: "Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer", CLIN. ENDOCRINOL, vol. 41, no. 4, 1994, Oxford, pages 525 - 30, XP002128735 *

Also Published As

Publication number Publication date
WO1996040150A1 (en) 1996-12-19
AU5984196A (en) 1996-12-30
EP0833641A1 (de) 1998-04-08
JPH11507050A (ja) 1999-06-22
CA2222625A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
EP0925046A4 (de) Topische zubereitungen und verfahren zur behandlung von hämorrhoiden
FI973163L (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
EP0801646A4 (de) Arzneimittel zur prophyzaxe und zur behandlung von erkrankungen des zentralen nervensystem
MA23941A1 (fr) Traitement des tissus
EP0888053A4 (de) Verfahren zur behandlung von krebs und infektionskrankheiten und dafür verwendbare zusammensetzungen
EP0754042A4 (de) Behandlung von atherosklerose mit imidazolen, die den angiotensin ii-rezeptor blockieren
DE69622993D1 (de) Sanft behandeltes ungekrepptes durchblasgetrocknetes tissue
EP0979074A4 (de) Behandlung oder vorbeugung klimakteriumsymptomen und der osteoporose
ID25504A (id) Pencegahan dan pengobatan penyakit amiloidogenik
ATE205365T1 (de) Enzymatische behandlung von kakao
EP0831904A4 (de) Behandlung und diagnose von prostatakrebs
GB9620892D0 (en) Methods of treating RAF mediated diseases
FI956339A0 (fi) Hypotalaamisen kuukautisten puuttumisen hoitaminenHypotalaamisen kuukautisten puuttumisen hoitaminen
NO965563D0 (no) Behandling og profylakse av osteoporese
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
EP0832204A4 (de) Behandlung der insulinresistenz
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
EP0752880A4 (de) Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i
EP1058546A4 (de) Zusammenstellungen und methoden zur behandlung von erkrankungen der macula
FI952176A7 (fi) Suovan neutralointi
ZA971607B (en) Methods of treatment of allergic diseases
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
DE69520268D1 (de) Behandlung von Legierungen und danach hergestellte Gegenstände
EP0800396A4 (de) Behandlung hyperandrogener zustände
EP0866799A4 (de) Apolipoprotein e2 und behandlung der alzheimerschen krankheit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000221

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000426